A “search and destroy” treatment has been found to halt tumours in some men with incurable prostate cancer. The early-stage ...

FDA approves Pylarify TruVu, a new prostate cancer PET imaging agent designed to expand access and improve detection of recurrent or metastatic disease.

At the 2026 Genitourinary Cancers Symposium in San Francisco, CA, Madan discusses a study investigating short-course (3-month ...

PSMA-PET molecular imaging more often triggers changes in salvage radiation treatment compared with usual care. Prostate-specific membrane antigen positron emission tomography (PSMA-PET) imaging ...

A panel of experts offers guidance for selecting patients with mCRPC for treatment with 177Lu-PSMA-617 and for managing treatment-related toxicities. The treatment is approved for use in men with ...

Bayer today announced results from the ongoing global Phase I first-in-human, dose-escalation PAnTHa study (NCT06217822) evaluating the safety, tolerability and preliminary efficacy of ...

Actinium-225 is a targeted and highly-potent alpha emitter that holds promise for patients who do not respond to lutetium-177 therapy. Rahul Parikh, MD, PhD, of University of Kansas, shared his ...

Reston, VA—Extended prostate-specific membrane antigen (PSMA)-targeted radiopharmaceutical therapy (177 Lu-PSMA) beyond six cycles is an effective and well-tolerated treatment for metastatic ...

Over the past decade or so, prostate-specific membrane antigen (PSMA) PET/CT has increasingly replaced conventional imaging in men with biochemical recurrence after radical prostatectomy. PSMA PET/CT ...

@2024 - All Right Reserved.

The researchers also assessed a prognostic biomarker, fluorodeoxyglucose (FDG) PET. A high volume of disease on FDG-PET (metabolic tumor volume [MTV] > 200 mL) was associated with a worse prognosis ...

Longitudinal PRO modeling, rather than time-to-worsening censoring, indicated maintained HRQOL and pain outcomes with ...